Brief: Hutchmed (China) Says Weiguo Su Takes Leave As CEO Due To Health Reasons
25/08/2025 02:10
Aug 25 (Reuters) - HUTCHMED (China) Ltd 0013.HK: WEIGUO SU TAKES LEAVE AS CEO DUE TO HEALTH REASONS JOHNNY CHENG APPOINTED ACTING CEO OF HUTCHMED Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation